OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients

Joel D Kopple; Alfred K Cheung; Jens Sandahl Christiansen; Christian Born Djurhuus; Meguid El Nahas; Bo Feldt-Rasmussen; William E Mitch; Christoph Wanner; Marie Göthberg; Talat Alp Ikizler

doi:10.1093/ndt/gfr363

OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients

Joel D Kopple, Alfred K Cheung, Jens Sandahl Christiansen, Christian Born Djurhuus, Meguid El Nahas, Bo Feldt-Rasmussen, William E Mitch, Christoph Wanner, Marie Göthberg, Talat Alp Ikizler

38 Citationer (Scopus)

Abstract

Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY™ Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.

Originalsprog	Engelsk
Tidsskrift	Nephrology, Dialysis, Transplantation
Vol/bind	26
Udgave nummer	12
Sider (fra-til)	4095-103
Antal sider	9
ISSN	0931-0509
DOI	https://doi.org/10.1093/ndt/gfr363
Status	Udgivet - 2011

Adgang til dokumentet

10.1093/ndt/gfr363

Citationsformater

@article{9e080000574d4876a6840f505bef296c,

title = "OPPORTUNITY{\texttrademark}: a large-scale randomized clinical trial of growth hormone in hemodialysis patients",

abstract = "Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY{\texttrademark} Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.",

author = "Kopple, {Joel D} and Cheung, {Alfred K} and Christiansen, {Jens Sandahl} and Djurhuus, {Christian Born} and {El Nahas}, Meguid and Bo Feldt-Rasmussen and Mitch, {William E} and Christoph Wanner and Marie G{\"o}thberg and Ikizler, {Talat Alp}",

year = "2011",

doi = "10.1093/ndt/gfr363",

language = "English",

volume = "26",

pages = "4095--103",

journal = "Nephrology, Dialysis, Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients

AU - Kopple, Joel D

AU - Cheung, Alfred K

AU - Christiansen, Jens Sandahl

AU - Djurhuus, Christian Born

AU - El Nahas, Meguid

AU - Feldt-Rasmussen, Bo

AU - Mitch, William E

AU - Wanner, Christoph

AU - Göthberg, Marie

AU - Ikizler, Talat Alp

PY - 2011

Y1 - 2011

N2 - Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY™ Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.

AB - Adult maintenance hemodialysis (MHD) patients experience high mortality and morbidity and poor quality of life (QoL). Markers of protein-energy wasting are associated with these poor outcomes. The OPPORTUNITY™ Trial examined whether recombinant human growth hormone (hGH) reduces mortality in hypoalbuminemic MHD patients. Secondary end points were effects on number of hospitalizations, cardiovascular events, lean body mass (LBM), serum proteins, exercise capacity, QoL and adverse events.

U2 - 10.1093/ndt/gfr363

DO - 10.1093/ndt/gfr363

M3 - Journal article

C2 - 21750157

SN - 0931-0509

VL - 26

SP - 4095

EP - 4103

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

IS - 12

ER -

OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater